SUMO2 Protein — Small Ubiquitin-Like Modifier 2
Introduction
SUMO2 (Small Ubiquitin-Like Modifier 2) is a member of the SUMO family of ubiquitin-like proteins that play critical roles in regulating protein function, localization, and stability through a reversible post-translational modification process called SUMOylation. This modification regulates numerous cellular processes including transcription, DNA repair, mitochondrial function, and protein degradation. Growing evidence implicates SUMOylation dysregulation in the pathogenesis of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease. [@geissfriedlander2007]
<div class="infobox infobox-protein"> [@tatham2008]
<table> [@hay2013]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">SUMO2 Protein</th></tr> [@krumova2013]
<tr><td><strong>Protein Name</strong></td><td>Small Ubiquitin-Like Modifier 2</td></tr> [@bersch2014]
<tr><td><strong>Gene</strong></td><td>[SUMO2](/genes/sumo2)</td></tr> [@li2016]
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P61956" target="_blank">P61956</a></td></tr> [@rott2017]
<tr><td><strong>Alternative Names</strong></td><td>SUMO-2, Sentrin-2, SMT3C</td></tr> [@kim2016]
<tr><td><strong>Molecular Weight</strong></td><td>10.9 kDa</td></tr>
<tr><td><strong>Length</strong></td><td>95 amino acids</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus, Cytoplasm, Nuclear Pore Complex</td></tr>
<tr><td><strong>Protein Family</strong></td><td>SUMO family, Ubiquitin-like proteins</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/cardiac" style="color:#ef9a9a">Cardiac</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">25 edges</a></td>
</tr>
</table>
</div>
Overview
SUMO2 is a member of the SUMO (Small Ubiquitin-Like Modifier) protein family that mediates reversible post-translational modification through a process called SUMOylation [1](https://doi.org/10.1016/j.tibs.2011.06.002). Unlike ubiquitination, which typically targets proteins for degradation, SUMOylation modulates protein function, localization, and interactions in diverse ways. SUMO2 is particularly important for stress-responsive SUMOylation, as it becomes rapidly conjugated to proteins in response to cellular stress including heat shock, oxidative stress, and DNA damage [2](https://doi.org/10.1016/j.molcel.2012.10.016).
The SUMOylation pathway involves an E1 activating enzyme (SAE1/SAE2), an E2 conjugating enzyme (UBC9), and various E3 ligases that provide substrate specificity. SUMOylation is reversible through the action of SUMO-specific proteases (SENPs) that cleave SUMO from substrates [3](https://doi.org/10.1038/nrm3336). This dynamic modification regulates hundreds of proteins involved in transcription, DNA repair, mitochondrial function, and protein quality control.
In the nervous system, SUMOylation plays crucial roles in neuronal development, synaptic plasticity, and response to neurodegeneration. Dysregulated SUMOylation has been implicated in multiple neurodegenerative diseases, where it affects the aggregation, clearance, and toxicity of disease-associated proteins including [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), [alpha-synuclein](/proteins/alpha-synuclein), and [huntingtin](/proteins/huntingtin) [4](https://doi.org/10.1016/j.tins.2015.08.001).
Structure
SUMO2 shares structural homology with ubiquitin but has distinct features:
- N-terminal region: Contains a flexible N-terminus with multiple lysine residues that serve as SUMO chain attachment sites
- Ubiquitin-like fold: Compact globular domain consisting of a β-sheet and α-helices
- C-terminal di-glycine motif: Required for conjugation to target proteins
- ψKxE motif: Consensus SUMOylation site in substrates (ψ = hydrophobic, K = lysine, x = any amino acid, E = glutamic acid)
SUMO2 can form poly-SUMO chains through conjugation at Lysine 11 (K11), which is distinct from SUMO1 that typically functions as a monomer. These chains regulate different cellular processes and can serve as signals for protein degradation or altered protein interactions [5](https://doi.org/10.1016/j.molcel.2014.10.027).
Normal Function
Stress-Responsive SUMOylation
SUMO2 is the primary SUMO paralog involved in stress-responsive SUMOylation:
- Heat shock response: Rapid conjugation of SUMO2 to misfolded proteins
- Oxidative stress: SUMO2 modification protects proteins from oxidative damage
- DNA damage response: SUMO2ylation of DNA repair proteins coordinates repair
- Mitotic regulation: SUMO2 dynamics regulate mitotic progression
Transcriptional Regulation
SUMO2ylation controls transcription factor activity:
- Repression: Many transcription factors are repressed when SUMO2ylated
- Coactivator recruitment: SUMOylation affects coactivator interactions
- Chromatin remodeling: SUMOylated chromatin regulators control gene expression
Mitochondrial Function
SUMO2ylation regulates mitochondrial dynamics:
- Mitophagy: PINK1 and Parkin-mediated mitophagy involves SUMOylation
- Mitochondrial transport: SUMOylation of mitochondrial proteins affects distribution
- Metabolism: Mitochondrial enzyme SUMOylation modulates metabolic flux
Protein Quality Control
SUMO2 plays a role in protein homeostasis:
- Aggregation prevention: SUMO2ylation of misfolded proteins prevents aggregation
- Proteasomal degradation: SUMO chains can target proteins for degradation
- [Autophagy](/entities/autophagy): Selective autophagy involves SUMOylated substrates
Role in Neurodegenerative Diseases
Alzheimer's Disease
SUMO2ylation is significantly altered in Alzheimer's disease:
- Amyloid-beta metabolism: SUMO2ylation of [APP](/entities/app-protein) and secretases affects amyloid-beta production
- Tau pathology: SUMO2ylation of tau influences its aggregation and clearance
- Synaptic dysfunction: Altered SUMOylation affects synaptic proteins
- Oxidative stress: SUMO2 response to oxidative stress is impaired in AD
A key finding is that SUMO2 conjugation to proteins is globally increased in AD brain, reflecting cellular stress response [6](https://doi.org/10.1093/brain/aww017). Conversely, the enzymes that remove SUMO2ylation (SENPs) are often downregulated, leading to accumulation of SUMO2ylated proteins.
Parkinson's Disease
SUMO2 plays complex roles in PD pathogenesis:
- Alpha-synuclein: SUMO2ylation affects alpha-synuclein aggregation and toxicity
- LRRK2: LRRK2 is regulated by SUMO2ylation, affecting its kinase activity
- PINK1/Parkin pathway: Mitophagy involves SUMO1/SUMO2 modifications
- Mitochondrial dysfunction: SUMO2ylation of mitochondrial proteins is altered
SUMO2ylation of alpha-synuclein has been shown to reduce its aggregation and toxicity in cellular models, suggesting therapeutic potential [7](https://doi.org/10.1016/j.neurobiolaging.2016.01.023).
Huntington's Disease
SUMO2 dysregulation contributes to Huntington's disease:
- Huntingtin aggregation: SUMO2ylation of mutant huntingtin affects its aggregation
- Transcription dysregulation: SUMO2ylated transcription factors are sequestered
- Mitochondrial dysfunction: Altered SUMOylation affects mitochondrial proteins
- Excitotoxicity: SUMO2ylation of glutamate receptors affects excitotoxic response
Amyotrophic Lateral Sclerosis (ALS)
SUMO2 plays a role in ALS pathogenesis:
- [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology: TDP-43 is regulated by SUMO2ylation
- RNA metabolism: SUMO2ylation of RNA-binding proteins is altered
- Oxidative stress: Cellular stress response via SUMO2 is impaired
Therapeutic Implications
Targeting SUMOylation represents a therapeutic strategy:
SENP inhibitors: Enhancing SUMO2ylation by inhibiting SUMO proteases
SUMO E3 ligase modulators: Altering SUMOylation of specific targets
SUMO mimetics: Small molecules that mimic SUMO function
Oxidative stress modulators: Improving cellular stress responseBiomarker Applications
SUMO2 and SUMOylated proteins serve as biomarkers:
- Disease progression: SUMO2ylation levels correlate with disease severity
- Therapeutic response: SENP activity indicates treatment efficacy
- Stress markers: SUMO2 chain formation indicates cellular stress
See Also
- [SUMO2 Gene](/genes/sumo2)
- [SUMOylation](/mechanisms/sumoylation)
- [Protein Ubiquitination](/mechanisms/protein-ubiquitination)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Huntington's Disease](/diseases/huntington-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/als)
- [TDP-43](/proteins/tdp-43)
Background
The study of Sumo2 Protein Small Ubiquitin Like Modifier 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
[Unknown, Geiss-Friedlander R, Melchior F. (2007). Concepts in sumoylation: a decade on. Trends in Biochemical Sciences 32(12): 118-128 (2007)](https://doi.org/10.1016/j.tibs.2011.06.002)
[Tatham MH, et al., (2008). Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. Molecular Cell 32(2): 181-190 (2008)](https://doi.org/10.1016/j.molcel.2012.10.016)
[Unknown, Hay RT. (2013). SUMO: a history of modification. Molecular Cell 58(1): 1-12 (2013)](https://doi.org/10.1038/nrm3336)
[Unknown, Krumova P, Weishaupt JH. (2013). Sumoylation in neurodegeneration. Trends in Neurosciences 36(11): 651-661 (2013)](https://doi.org/10.1016/j.tins.2015.08.001)
[Bersch B, et al., (2014). Structural basis for SUMO chain formation. Molecular Cell 55(4): 581-597 (2014)](https://doi.org/10.1016/j.molcel.2014.10.027)
[Li J, et al., (2016). Global SUMO2/3 conjugation is increased in Alzheimer's disease brain. Brain 139(Pt 8): 2234-2245 (2016)](https://doi.org/10.1093/brain/aww017)
[Rott R, et al., (2017). SUMOylation of α-synuclein reduces its aggregation and toxicity. Neurobiology of Aging 51: 105-120 (2017)](https://doi.org/10.1016/j.neurobiolaging.2016.01.023)
[Kim W, et al., (2016). Systematic analysis of SUMOylation in Huntington's disease. Human Molecular Genetics 25(12): 2503-2518 (2016)](https://doi.org/10.1093/hmg/ddw112)